AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06473935 — intervention group
Intervention type: OTHER
Intervention: Questionnaires and focus groups
Description: Participation in the research involves completing a test battery composed of self-administered questionnaires, all validated in the Italian language.~Additionally, qualitative data will be collected through semi-structured interviews (conducted in person or online, based on individual preferences) and focus groups, both lasting between 90 and 120 minutes.
Study NCT05577546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moor S brace treatment
Description: The rigid MOOR-S Brace controls the thoracic, lumbar and pelvis blocks very tightly, is modelled and produced according to deformity type and patients body size considering the standardization of the MOOR-S Model. It is a CAD-CAM design-based rigid torocolumbosacral orthosis, using polypropylene material, which is opened from the front, and tightness can be adjusted by the patients with the help of straps. Additional corrective forces can be applied with pads that can be added to the brace. The amount of corrective forces in the MOOR-S brace is decided by the experienced orthotist, taking into account risk of progression, the flexibility of the spine deformity, Cobb angle, bone maturation and age. An external stimulus is provided that directs the protracted shoulder to slightly to the posterior by the shoulder part, located on the anterosuperior side of the brace.
Study NCT05577546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Schroth Three-Dimensional Scoliosis Exercise Treatment
Description: Schroth Three-Dimensional Scoliosis Exercise Treatment has the main features of physiotherapeutic scoliosis-specific exercises: 1) Three-dimensional self-correction, 2) Training activities of daily living (ADL), and 3) Stabilization of the corrected posture. The basic principles of the Schroth method are autoelongation, deflection, derotation, rotational angular breathing and stabilization. Exercise therapy will be carried out at the brace center once a week with the researcher, and 45 min a day, 4 days a week in the form of home exercises. The number of exercise sets and repetitions will be determined by the physiotherapist according to the patient, considering deformity severity and flexibility, generalized joint hypermobility, bone maturation, menarche status and the risk of progression. Compliance with the home exercise program (frequency and duration) will be recorded by the patients in a home exercise diary for 12 weeks.
Study NCT04797949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose aspirin
Description: Women will be prescribed 81 mg of aspirin to take daily during pregnancy.
Study NCT05718258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venglustat (GZ402671)
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT05979857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-3164
Description: SP-3164, an oral next generation cereblon-binding molecular glue 'protein degrader'
Study NCT05219669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalmefene Hydrochloride
Description: 30 mg/mL solution
Study NCT05429073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGLS8429
Description: solution for subcutaneous injection
Study NCT05429073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo volume-matching RGLS8429 dose
Description: solution for subcutaneous injection
Study NCT04528433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical-education-community Collaborated Intervention
Description: The Medical-education-community Collaborated Intervention adds an additional part in comparison with the control group of classroom management guidance for teachers, review and practice organizational skills based on school daily activities in the school, teacher rewards and encouragement of students.
Study NCT05681260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin
Description: Standard risk Arm A: Induction I followed by Consolidation, extracompartmental Capizzi MTX, delayed intensification and 96 weeks' maintenance therapy. Twenty-one or twenty-six triple intrathecal injections for CNS negative or positive patients, respectively.
Study NCT05681260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin
Description: Standard risk Arm B: Induction I followed by Consolidation, extracompartmental high dose MTX, delayed intensification and 96 weeks' maintenance therapy. Twenty-one or twenty-six triple intrathecal injections for CNS negative or positive patients, respectively.
Study NCT05681260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin, Vindesine, Etoposide, Ifosfamide
Description: High Risk T-LBL: Induction I followed by 2 cycles of BFM HR Blocks, delayed intensification and 96 weeks' maintenance therapy. Twenty-four or twenty-eight triple intrathecal injections for CNS negative or positive patients, respectively.
Study NCT05102383 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comfilcon A Toric contact lenses
Description: Monthly replacement contact lenses
Study NCT05102383 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verofilcon A for Astigmatism Daily Disposable contact lenses
Description: Daily disposable contact lenses
Study NCT05227794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion Cultivation Training (CCT)
Description: CCT is a secular, empirically supported 8-week program that integrates meditation practices, interactive discussions, and educational lectures to improve self-compassion and other-oriented compassion, emotion and stress management, and happiness and well-being. It includes a weekly 2-hour educational lecture with discussion and in-class exercises, a recommendation of 15-30 minutes of daily meditation, and real-world assignments to practice compassion. The program is taught by a certified instructor with more than 5 years experience.
Study NCT05227794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Description: MBSR is among the most studied mindfulness-based interventions in the literature and is a secular, 8-week psycho-educational group-based intervention. The program structure (slightly modified to match CCT) includes a weekly 2-hour class, a prescription of 15-30-minutes of daily mindfulness practice, and a one-day optional retreat (6 hours) between week six and seven. The program is taught by a certified instructor with more than 5 years experience.
Study NCT04528433 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: routine clinical care
Description: Routine clinical care includes a structured family behavioral intervention for ADHD symptom management and organizational skill training, the medication will be used if necessary.
Study NCT05807815 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Titration of fraction of inspired oxygen (FiO2) guided by ORI and oxygen saturation
Description: FiO2 will be titrated by reducing 10% if Ori>0.01 and oxygen saturation ≥ 98% until Ori is 0.00.~FiO2 will not be changed if Ori is 0.00 and %95\<oxygen saturation≤%98 FiO2 will be increased by 10% if oxygen saturation \<95 or PaO2\<60 mmHg
Study NCT06403735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLC1101
Description: QLC1101 is an innovative small molecule inhibitor targeting KRAS G12D with independent intellectual property rights developed by Qilu Pharmaceutical Co., Ltd.QLC1101 can prevent GTP/GDP nucleotide exchange and/or the formation of KRAS G12D/GTP/RAF1 complex and inhibit mutant KRAS-dependent signal transduction by specifically binding to the KRAS G12D target, thereby inhibiting the generation of KRAS G12D mutant tumors.
Study NCT05762900 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultra-fractionated radiation therapy
Description: 5.2Gy per fraction for 5 fractions with an integrated boost of 6Gy per fraction.
Study NCT05130931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal conservative treatment
Description: 15 min of Pain education + 20 min of Specific mobilization of the forearm musculature, pronator teres, tendons of the palmar flexors of the wrist and fingers, transverse carpal ligament and palmar fascia through manual mobilization assisted by Diacutaneous Fibrolysis technique + 10min of self-management and explanation of home-based exercise.~3 sessions of 45 minutes will be taken to perform this protocol and the patient will be shown a self-treatment to be performed 3-5 times a day. The protocol will be carried out over 3 weeks (1 session per week).
Study NCT06412952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-RM26
Description: Intravenous injection of one dosage of 74-185 MBq(2-5 mCi) 68Ga-RM26. Tracer doses of 68Ga- RM26 will be used to image lesions of glioma by PET/CT.
Study NCT05147493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Route of administration: Intravenous (IV). Dose regimen: Isatuximab will be given at a dose of 10 mg/kg once weekly (QW) on Days 1, 8, 15, and 22 in Cycle 1, on Days 1 and 15 during Cycles 2-6 and on Day 1 from Cycle 7 onwards.
Study NCT05147493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Route of administration: Subcutaneous (SC). Dose regimen: Bortezomib will be given at 1.3 mg/m2 on Days 1, 4, 8, 11 of Cycle 1 and days 1, 8, 15, 22 of Cycles 2-6.
Study NCT05147493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Route of administration: Intravenous (IV). Dose regimen: Cyclophosphamide will be given at 300 mg/m2on Days 1, 8, 15 of Cycle 1 and days 1, 8, 15, 22 of Cycles 2-6.
Study NCT05147493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Route of administration: per os (PO)/Intravenous (IV). Dose regimen: Dexamethasone will be given at 40 mg (20 mg for ≥75 years old) on Days 1-4 and 9-12 of Cycle 1 and Days 1, 8, 15 and 22 of Cycles 2-6.
Study NCT05147493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Route of administration: per os (PO). Dose regimen: Lenalidomide will be given at 10 mg (or according to renal function) daily from Cycle 7 onwards.
Study NCT04881708 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Monitoring
Description: Subjects assigned to the Remote Care group will receive education from a clinical nurse from Mayo Clinic's Department of Connected Care on use of the equipment as part of Remote Monitoring. The equipment will be shipped along with instructions and Welcome Letter describing the Mayo Clinic Remote Patient Monitoring program. The Remote Patient Monitoring kit includes a digital tablet, a blood pressure cuff, a thermometer, a pulse oximeter, and a weight scale. Subjects will be contacted by phone at the end of the study to be instructed how to return the kit by mail.
Study NCT05583149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACALABRUTINIB
Description: Oral, twice daily, timing and dosage per protocol
Study NCT05583149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LISOCABTAGENE MARALEUCEL
Description: via IV timings and dosage per protocol
Study NCT05583149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lymphodepleting chemotherapy
Description: lymphodepleting chemotherapy with cyclophosphamide and fludarabine once a day for 3 days via IV about 2-4 hours. This will occur only once prior to lisocabtagene maraleucel infusion.
Study NCT05793606 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deltoid ligament repair
Description: Surgical repair for the deltoid ligament
Study NCT05623215 — intervention group
Intervention type: RADIATION
Intervention: Radiographs of the knee for radiostereometric analysis (RSA)
Description: RSA radiographs will be made 5 and 10 years after the total knee arthroplasty.
Study NCT04679909 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCOVID
Description: Administered intranasally
Study NCT04679909 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered intranasally
Study NCT04787380 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heartfelt device
Description: The Heartfelt device uses a system of cameras in a compact device to generate 3D images of the feet and lower legs with a view to detecting early volume changes. The device can be installed on the wall or as a free standing unit; however, given the COVID-19 pandemic, only the free standing option will be available to participants, so as to avoid the necessity of an installer visiting the patient. For the measurements to take place, the participant walks in the field of view of the device. Participants are not expected to change anything to their routine. The device can also take measurements in the dark.~The switch between 'full data analysis' and 'technical checks only' modes can be done remotely, making the cross-over seamless.~In the event that an alert is generated by the device, a medical assessment will take place either by phone or face to face appointment to evaluate the participant's condition.
Study NCT05296980 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REMINDER
Description: The REMINDER program is a therapist-mediated manualized neuropsychological intervention, involving training skills to stimulate cognitive reserve, socialization and personal development, to diminish the risk of cognitive decline.
Study NCT05296980 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Brain health Psychoeducation
Description: Delivery of psychoeducation sessions about dementia modifiable risk factors, brain health solutions and lifestyle change tips.
Study NCT05549154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D2 softgels
Description: 5000U/capsule of vitamin D2 soft capsule; High-dose VD group 50,000 U/week, 5 vitamin D2 softgels given twice a week each time; 25(OH)D > 80ng/ml after 3 months of intervention or within 3 months in both groups, changed to 5,000 U/ weekly maintenance until the full 6 months of intervention. To prevent unmasking, the maintenance dose was still given twice weekly (the first time 1 vitamin D2 capsule + 4 placebo capsules were given and the second time 5 placebo capsules were given)
Study NCT05549154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose vitamin D2 softgels
Description: 5000U/capsule of vitamin D2 soft capsule; low-dose VD group 25,000 U/week, 3 vitamin D2 softgels + 2 placebo in the first dose, 2 vitamin D2 softgels + 3 placebo in the second dose, 25(OH)D > 80ng/ml after 3 months of intervention or within 3 months in both groups, changed to 5,000 U/ weekly maintenance until the full 6 months of intervention. To prevent unmasking, the maintenance dose was still given twice weekly (the first time 1 vitamin D2 capsule + 4 placebo capsules were given and the second time 5 placebo capsules were given);
Study NCT05549154 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo was filled with excipients (aniseed ether, refined vegetable oil), and the shape and size were the same as vitamin D2 soft capsule.the control group was given placebo, 5 placebo capsules twice weekly for 6 months of the intervention. The medication was dispensed by a designated person (not the investigator) in advance and independently according to the patient's medication number (only the drug number was provided on the outer packaging).
Study NCT06272032 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity focused ultrasound (HIFU)
Description: Ultrasound is a type of mechanical vibrational wave capable of penetrating living tissues without causing harm to the tissue. As a non-invasive physical modality, ultrasound boasts advantages such as non-invasive safety, excellent directional propagation, strong penetration capability, and optimal focusing effects. It can induce a series of structural and functional changes in tissue cells through actions like cavitation, mechanical force vibration, and heat generation, leading to corresponding clinical effects. Clinical studies have demonstrated that focused ultrasound not only improves symptoms of allergic rhinitis (AR) but also holds certain advantages in preserving the structural and functional integrity of the nasal mucosa.
Study NCT06202391 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autogenic Inhibition-MET
Description: Autogenic Inhibition-MET protocol: 3-5 repetitions of post isometric relaxation (PIR) (30- 50% isometric contraction of the muscle to be stretched for 5-10 seconds, followed by rest period of 5 seconds and then a stretch of 20-30 seconds' hold. A total of 12 sessions, four times a week, for three consecutive weeks.
Study NCT06202391 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reciprocal Inhibition-MET protocol
Description: Reciprocal Inhibition-MET protocol: 3-5 repetitions of Reciprocal Inhibition (RI) MET (30- 50% isometric contraction of the muscle opposite to the muscle to be stretched for 5-10 seconds, followed by rest period of 5 seconds and then a stretch of 20-30 seconds' hold A total of 12 sessions, four times a week, for three consecutive weeks
Study NCT06320145 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: This device used at the first, second and third day of period to decrease pain for 20 min at first, second and third day
Study NCT06320145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: core stability exercises
Description: core stability exercises
Study NCT05985655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTAEXS617
Description: GTAEXS617 tablets daily
Study NCT06272032 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intranasal corticosteroids, oral antihistamines, oral leukotriene receptor antagonists, and intranasal antihistamines
Description: intranasal corticosteroids, oral antihistamines, oral leukotriene receptor antagonists, and intranasal antihistamines and other therapies.
Study NCT06377137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Small-sided soccer games groups (SSSG)
Description: Physical exercise intervention
Study NCT06377137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional soccer training groups (TSG)
Description: Physical exercise intervention
Study NCT05395299 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SQUID (Ethylene Vinyl Alcohol Copolymer ) administred to the participant with the intervention Prostatic Arterial Embolization
Description: Prostatic Arterial Embolization with SQUID (Ethylene Vinyl Alcohol Copolymer )
Study NCT06125730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DIME Beauty Eyelash Boost Serum
Description: The test product contains Water, Glycerin, Amino Acids (Sodium PCA, Sodium Lactate, Arginine, Aspartic Acid, PCA, Glycine, Alanine, Serine, Valine, Proline, Threonine, Isoleucine, Histidine, Phenylalanine), Hyaluronic Acid, Panthenol, Aloe Leaf Extract, Niacinamide, Purslane, Chebulic Fruit Extract, Apple Fruit Extract, Tocopherol, Phenoxyethanol, Hexanediol, Ethylhexylglycerin, Biotinoyl Tripeptide-1, Myristoyl Pentapeptide-4.
Study NCT04727801 — intervention group
Intervention type: DEVICE
Intervention: Verily Patch
Description: The Verily Patch is an investigational wearable temperature sensor that consists of a Patch (Verily Patch), with swappable adhesives, as well as an app (Verily Patch app).
Study NCT05739149 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Microvessel Ultrasound Examination
Description: Ultrasound to evaluate microvessel formation and elastography or stiffness of the tissues around the ulcer and in an area of unaffected skin
Study NCT05739149 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin Biopsy
Description: Dermatology will remove a small piece of skin from the affected ulcer area and control skin
Study NCT04652479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avexitide
Description: Avexitide (exendin 9-39) is a competitive antagonist of GLP-1 at its receptor
Study NCT06390969 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Cross-sectional online survey
Study NCT04809974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niagen
Description: The intervention consists of taking Niagen and completing all tasks divided into 6 visits.
Study NCT04809974 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Niagen
Description: The intervention consists of taking Niagen and completing all tasks divided into 6 visits.
Study NCT05436847 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Training
Description: Proprioceptive Training using increased joint to joint approximation through ankle weights and joint splints.
Study NCT05436847 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Physical Therapy
Description: Neurodevelopmental treatment- age appropriate
Study NCT02871232 — intervention group
Intervention type: OTHER
Intervention: Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) System of post-marketing surveillance of prescription medication abuse, misuse, and diversion
Study NCT02512432 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: INTACS
Description: asymmetrical corneal inserts to reduce, or eliminate myopia and astigmatism in patients with keratoconus to decrease dependence on contact lenses and spectacle correction, while potentially deferring need for corneal transplantation.